Conditionally Active, Dual-Targeting BiTAC-TCEs for the Treatment of Solid Tumours
- Our BiTAC-TCE platform is designed to overcome the on-target, off-tumour toxicities of conventional (mono-targeting) TCEs
- AND-gated targeting of antigen pairs together with an on-cell assembly of a split anti-CD3 increases the selectivity to dual antigen-positive tumour cells
- In vitro and in vivo data of several programs including our most advanced preclinicalstage* EpCAM-targeting BiTAC-TCE will be presented